Mono- and Diglycerides vs Erythritol: which is worse?

What is Mono- and Diglycerides?

Mono- and diglycerides are emulsifiers derived from glycerol and fatty acids, most commonly sourced from soybean, palm, or sunflower oil. They are partial glycerides that exist between monoglycerides (one fatty acid chain) and diglycerides (two chains). They are chemically similar to fats but are not classified as trans fats even when made from partially hydrogenated sources.

What is Erythritol?

Erythritol is a four-carbon sugar alcohol naturally occurring in small amounts in fruits, fermented foods, and mushrooms. Commercially produced via fermentation of glucose by yeasts such as Moniliella pollinis, it has approximately 70% of sucrose's sweetness, provides 0.24 kcal/g, and has a glycemic index of 0. It is nearly completely absorbed in the small intestine and excreted unchanged in urine, which explains its unusually low laxative effect compared to other polyols.

Documented risks

Mono- and Diglycerides: Generally recognized as safe at typical food levels. However, mono- and diglycerides can be derived from partially hydrogenated oils, meaning they may carry trace trans fats that do not appear on the trans fat label because they are classified as emulsifiers, not fats. Some researchers have noted this labeling gap. A 2019 study published in Lipids in Health and Disease noted potential concerns with industrial trans fatty acids in these additives. For most consumers, exposure is low, and regulatory agencies including FDA and EFSA consider them safe at permitted levels.

Erythritol: A 2023 observational study published in Nature Medicine (Hazen et al., Cleveland Clinic) found that elevated blood erythritol levels were associated with increased risk of major adverse cardiovascular events (MACE), including heart attack and stroke. Additionally, erythritol was found to enhance platelet aggregation in vitro. This study was widely reported and has generated significant scientific debate; critics note that it was observational (not causational), and that the study population had pre-existing cardiovascular risk factors. Regulatory agencies have not changed their approval status. The long-term cardiovascular implications require further research.